Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) shares hit a new 52-week high during trading on Monday . The company traded as high as $5.09 and last traded at $4.95, with a volume of 559791 shares changing hands. The stock had previously closed at $4.70.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. Benchmark reaffirmed a "buy" rating and set a $15.00 target price on shares of Humacyte in a report on Monday. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 target price on shares of Humacyte in a research report on Monday, April 1st. Finally, Piper Sandler restated a "neutral" rating and set a $4.00 price target on shares of Humacyte in a research report on Tuesday, March 26th.
Check Out Our Latest Stock Analysis on Humacyte
Humacyte Stock Up 16.6 %
The company has a 50-day simple moving average of $3.52 and a 200 day simple moving average of $3.16. The company has a current ratio of 4.52, a quick ratio of 4.52 and a debt-to-equity ratio of 1.20. The company has a market cap of $652.56 million, a P/E ratio of -5.09 and a beta of 1.27.
Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same period last year, the company earned ($0.21) earnings per share. On average, equities analysts anticipate that Humacyte, Inc. will post -0.9 EPS for the current year.
Institutional Trading of Humacyte
A number of institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its stake in Humacyte by 261.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company's stock valued at $26,000 after buying an additional 6,504 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of Humacyte during the fourth quarter valued at about $28,000. Victory Capital Management Inc. purchased a new position in shares of Humacyte during the 4th quarter valued at approximately $29,000. SG Americas Securities LLC bought a new stake in shares of Humacyte in the 3rd quarter worth about $31,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Humacyte by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company's stock valued at $34,000 after buying an additional 9,325 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
